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Correlation Between Pathologic Complete Response in the Breast
and Absence of Axillary Lymph Node Metastases After
Neoadjuvant Systemic Therapy
Sanaz Samiei, MD,yz Thiemo J. A. van Nijnatten, MD, PhD,yz Linda de Munck, MSc,§
Kristien B. M. I. Keymeulen, MD, Janine M. Simons, MD, Loes F. S. Kooreman, MD,zjj
Sabine Siesling, MD, PhD,§ Marc B. I. Lobbes, MD, PhD,yz and Marjolein L. Smidt, MD, PhDz
Objective: The aim was to investigate whether pathologic complete response
(pCR) in the breast is correlated with absence of axillary lymph node
metastases at final pathology (ypN0) in patients treated with neoadjuvant
systemic therapy (NST) for different breast cancer subtypes.
Background: Pathologic complete response rates have improved on account
of more effective systemic treatment regimens. Promising results in feasibility
trials with percutaneous image-guided tissue sampling for the identification of
breast pCR after NST raise the question whether breast surgery is a redundant
procedure. Thereby, the need for axillary surgery should be reconsidered as
well.
Methods: Patients diagnosed with cT1-3N0-1 breast cancer and treated with
NST, followed by surgery between 2010 and 2016, were selected from the
Netherlands Cancer Registry. Patients were compared according to the
pathologic response of the primary tumor with associated pathologic axillary
outcome. Multivariable analysis was performed to determine clinicopatho-
logical variables correlated with ypN0.
Results: A total of 4084 patients were included for analyses, of whom 986
(24.1%) achieved breast pCR. In clinically node negative patients (cN0),
97.7% (432/442) with breast pCR had ypN0 compared with 71.6% (882/1232)
without breast pCR (P < 0.001). In clinically node positive patients (cN1),
45.0% (245/544) with breast pCR had ypN0 compared with 9.4% (176/1866)
without breast pCR (P < 0.001). The odds of ypN0 was decreased in case of
clinical T3 stage (OR 0.59, 95% CI 0.40–0.87), cN1 (OR 0.03, 95% CI 0.02–
0.04) and ERþHER2- subtype (OR 0.30, 95% CI 0.20–0.44), and increased
in case of breast pCR (OR 4.53, 95% CI 3.27–6.28).
Conclusions: Breast pCR achieved after NST is strongly correlated with
ypN0 in cN0 patients, especially in ERþHER2þ, ER-HER2þ, and triple
negative subtypes. These results provide data to proceed with future clinical
trials to investigate if axillary surgery can be safely omitted in these selected
patients when image-guided tissue sampling identifies a breast pCR.
Keywords: axillary surgery, breast cancer, neoadjuvant systemic therapy,
pathologic complete response
(Ann Surg 2020;271:574–580)
O ver recent years, systemic therapy in the treatment of breastcancer has increasingly been administered in the neoadjuvant
setting. The indication of neoadjuvant systemic therapy (NST)
has evolved from inoperable and locally advanced breast cancer
to early stage breast cancer patients with unfavorable tumor profiles.1
NST allows treatment response to be clinically assessed and can
lead to the treatment plan being modified in cases of poor response.2
It also offers the advantages of downsizing the primary tumor,
decreasing the incidence of positive lymph nodes, or even results
in complete eradication of cancer, so-called pathologic complete
response (pCR) of the breast tumor (hereinafter referred to as
breast pCR) and/or the axillary lymph nodes (ypN0).3,4 As
well as these NST advantages, previous studies have reported that
pCR in the breast and axilla is associated with superior survival
outcomes.5–7
Over the past decade, improvements in the efficacy of che-
motherapy and targeted therapies have increased pCR rates. A meta-
analysis, performed by Cortazar et al, found that breast pCR was
achieved in 22.0% of patients after NST with higher pCR rates in
HER2þ and triple negative breast cancer subtypes.8 Concerning
axillary lymph nodes, NST can eradicate metastases in clinically
node positive patients with a reported axillary pCR rate of 37.0%.9
The axillary pCR rate for HER2þ patients increases with the use of
HER2-targeted therapy to between 43% and 74%.6,7,10,11 Patients
who achieved axillary pCR were more likely to have breast
pCR.6,11,12
At present, surgery is the gold standard for determining
whether pCR after NST is achieved in breast cancer patients.
However, research is increasingly being conducted with the focus
on reducing or eliminating breast and/or axillary surgery. Promising
results in feasibility trials with percutaneous image-guided biopsy for
identifying breast pCR after NST raise the question of whether breast
surgery is becoming a redundant procedure in selected group of
patients with breast pCR.13–15 Since correlation between breast pCR
and axillary pCR has been suggested, the need for axillary surgery
should be reconsidered in the case of breast pCR.13,14 Evidence for
this correlation is limited, however, and not yet studied for different
breast cancer subtypes.
Therefore, we aimed to investigate whether breast pCR is
correlated with ypN0 in patients treated with NST for different breast
cancer subtypes.
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METHODS
In this study, 4084 consecutive patients were included who
had all been diagnosed with primary invasive breast cancer in the
Netherlands and treated with NST (chemotherapy with or without
trastuzumab) between January 2010 and September 2016. To be
considered for final analyses, patients needed to be staged as cT1-
3N0-1 breast cancer prior to NST administration. After the comple-
tion of NST, all patients underwent standard breast and axillary
surgery. Patients were excluded if the sentinel lymph node biopsy
(SLNB) had been performed before NST administration. Other
exclusion criteria were unknown pathological tumor stage, distant
metastases at primary breast cancer diagnosis or within 91 days after
surgery, unknown breast cancer subtype, neoadjuvant endocrine
therapy, or unknown number of lymph node metastases at final
pathology (Fig. 1).
The axillary nodal status was determined before NST admin-
istration by axillary ultrasound. If axillary ultrasound showed no
suspicious lymph nodes, patients were defined as clinically node
negative (cN0). If suspicious lymph nodes were confirmed with
additional fine-needle aspiration cytology (FNAC) or core needle
biopsy, patients were defined as clinically node positive (cN1).
If the patient was defined as cN0 before NST administration,
the patient underwent SLNB after NST. If the patient was classified
as cN1 before NST administration, the patient underwent axillary
lymph node dissection (ALND) after NST.
The 2008 and 2012 Dutch national guidelines were applied
during the 2010 to 2016 study period.16,17 These guidelines recom-
mended systemic therapy consisting of the following chemotherapeutic
regimens: 6 cycles of TAC (Taxotere, Adriamycin, Cyclofosfamide), or
3 cycles of FEC (Fluorouracil (5FU), Epirubicin, Cyclophosphamide),
or 4 cycles of AC (Adriamycine, Cyclophosphamide) followed by 12
cycles of paclitaxel or 4 cycles of docetaxel. In the case ofHER2þ breast
cancer, trastuzumab was recommended as the targeted therapy in
addition to chemotherapy and continued until 1 year after the start.
In the time frame2010 to 2016noHER2-targeted therapywas advised in
addition to trastuzumab.
HER2 status was evaluated with immunohistochemistry
(IHC). The IHC score of 0 or 1þ was considered negative (<10%
of the tumor cells are stained, or>10% of the tumor cells are stained,
with no circumferential staining and weak color intensity). In case of
a 2þ IHC score (>10% circumferential membrane staining with
moderate intensity), fluorescence in situ hybridization (FISH) was
mandatory in addition to IHC and the result of FISH overruled. The
IHC score of 3þ was considered positive (>30% of cells with strong
intensity circumferential membrane staining).
Data were obtained from the Netherlands Cancer Registry
(NCR) after this study had been approved by the Privacy Review
Board of NCR, managed by the Netherlands Comprehensive Cancer
Organisation (IKNL). On site trained registrars from the NCR extract
data from patients’ medical records after notification. Data were
9801 paents with cT1-3N0-1 
invasive breast cancer treated 
with NST in the Netherlands 
between 2010 - 2016
Reasons for exclusion (total n=5717):
- SLNB before NST (n=3114) 
- Axillary surgery unknown (n=882)
- No ALND in case of cN1 (n=615)
- Pathological tumor stage unknown (n=369)   
- Distant metastases (n=223)
- SLNB outcome not registered (n=216)                                    
- Subtype unknown (n=126)
- Neoadjuvant endocrine therapy (n=121)
- SLNB date not registered (n=38)
- Number of lymph nodes unknown (n=13)
585 ER+HER2+ 
subtype (14.3%)
361 ER-HER2+ 
subtype (8.8%)
2336 ER+HER2-
subtype (57.3%)
802 triple 
negave subtype 
(19.6%)
4084 included paents for 
ﬁnal analyses
FIGURE 1. Flow diagram of patient inclusion. ALND indicates axillary lymph node dissection; cN1, clinically node positive; ER,
estrogen receptor; HER2, human epidermal growth factor receptor 2; SLNB, sentinel lymph node biopsy; Triple negative, negative
for ER, PR and HER2.
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collected on age, tumor histology, receptor status, surgical proce-
dures, systemic therapy, radiation therapy, clinical TNM stage, and
pathology results, including stage after NST (ypTNM), tumor grade
and number of axillary lymph nodes with and without metastases.
Breast pCR was defined as the absence of both invasive and in situ
breast cancer, with ypN0 being defined as the absence of both macro-
and micrometastases in the axillary lymph nodes.18 Isolated tumor
cells were considered as ypN0.18
Statistical analyseswere performed byusingStatistical Package
for the Social Sciences software (SPSS, version 24, IBM, Armonk,
NY). Patients were subdivided into breast pCR or without breast pCR
for the following breast cancer subtypes: ER positive(þ)HER2þ, ER
negative()HER2þ, ERþHER2, and triple negative. For each
subtype, the number of axillary lymph nodes with and without
metastases at final pathology was reported. The x2 test and Fisher
exact test were used to compare patients with breast pCR and without
breast pCR. Univariable logistic regression analysis was conducted to
determine the association between relevant clinicopathological vari-
ables and ypN0. Multivariable analysis was performed to identify the
independent clinicopathological variables correlated with ypN0. Odds
ratios (ORs) with 95% confidence intervals (CIs) were calculated.
Two-sided P values of<0.05 were considered statistically significant.
RESULTS
Of the 4084 patients (median age, 49 yrs; range, 18–83 yrs)
included for analyses, 585 patients had ERþHER2þ, 361 ER-
HER2þ, 2336 ERþHER2 and 802 had triple negative breast
cancer subtype. A total of 1674 (41.0%) patients were cN0 and
2410 (59.0%) were cN1. Breast conserving surgery was performed in
1835 (44.9%) patients and 2249 (55.1%) underwent mastectomy.
SLNB was performed in 1483 (36.3%) patients and 2601 (63.7%)
underwent ALND (Table 1).
Overall, 986 out of 4084 patients (24.1%) achieved breast
pCR. Of the patients with breast pCR, 68.7% (677 of 986) had ypN0
compared with 34.2% (1058 of 3098) without breast pCR (P <
0.001). In the case of cN0, 97.7% (432/442) with breast pCR had
ypN0 compared with 71.6% (882/1232) without breast pCR (P <
0.001). In the case of cN1, 45.0% (245/544) with breast pCR had
ypN0 compared to 9.4% (176/1866) without breast pCR (P< 0.001)
(Table 2).
In univariable analysis, clinicopathological variables associ-
ated with lower odds of ypN0 were age 35 to 50 years (OR 0.70, 95%
CI 0.54–0.90, P < 0.006), age 50 to 75 years (OR 0.60, 95% CI
0.47–0.79, P < 0.001), clinical T3 stage (OR 0.51, 95% CI 0.41–
0.62, P < 0.001), cN1 stage (OR 0.06, 95% CI 0.05–0.07, P <
0.001), ERþHER2 subtype (OR 0.32, 95% CI 0.27–0.39, P <
0.001), and triple negative subtype (OR 0.31, 95% CI 0.26–0.37,
P< 0.001). Tumor grade 3 (OR 1.67, 95% CI 1.28–2.19, P ¼ 0.045)
and breast pCR (OR 4.22, 95% CI 3.62–4.93, P < 0.001) were
associated with higher odds of ypN0. In multivariable analysis after
correcting for confounders, the odds of ypN0was decreased in the case
of clinical T3 stage (OR0.59, 95%CI 0.40–0.87,P< 0.007), cN1 (OR
0.03, 95% CI 0.02–0.04, P < 0.001) and ERþHER2 subtype (OR
0.30, 95%CI0.20–0.44,P< 0.001), and increased in the case of breast
pCR (OR 4.53, 95% CI 3.27–6.28, P < 0.001) (Table 3).
ERRHER2R subtype
Trastuzumab in neoadjuvant setting was administered in 531
out of 585 (90.8%) ERþHER2þ patients. In this subtype, 236 out of
585 (40.3%) patients achieved breast pCR. In all ERþHER2þ
patients with breast pCR, 76.3% (180 of 236) had ypN0 compared
to 48.4% (169 of 349) without breast pCR (P< 0.001). In the case of
cN0 with breast pCR, only 2 out of 124 patients (1.6%) had 1 axillary
lymph node metastasis at final pathology, compared to 15.0% (23 of
TABLE 1. Overview of Patient, Tumor, and Treatment Characteristics
Total
(n ¼ 4084)
ERþHER2þ
(n ¼ 585)
ER-HER2þ
(n ¼ 361)
ERþHER2
(n ¼ 2336)
Triple Negative
(n ¼ 802)
Median age (yrs; range) 49 (18–83) 48 (18–75) 51 (23–81) 50 (24–76) 49 (24–83)
Clinical stage (%)
T1N0 294 (7.2) 59 (10.1) 15 (4.2) 159 (6.4) 61 (7.6)
T1N1 355 (8.7) 42 (7.2) 29 (8.0) 210 (9.8) 74 (9.2)
T2N0 1057 (25.9) 172 (29.4) 88 (24.4) 557 (20.2) 240 (30.0)
T2N1 1354 (33.2) 181 (30.9) 120 (33.2) 773 (36.2) 280 (34.9)
T3N0 323 (7.9) 46 (7.9) 25 (6.9) 216 (7.6) 36 (4.5)
T3N1 701 (17.1) 85 (14.5) 84 (23.3) 421 (19.8) 111 (13.8)
Tumor histology (%)
Ductal 3242 (79.4) 510 (87.2) 318 (88.1) 1725 (73.8) 689 (85.9)
Lobular 439 (10.7) 29 (5.0) 8 (2.2) 388 (16.6) 14 (1.7)
Mixed ductal and lobular 103 (2.5) 11 (1.9) 2 (0.6) 88 (3.8) 2 (0.2)
Other 300 (7.4) 35 (5.9) 33 (9.1) 135 (5.8) 97 (12.2)
Tumor grade (%)
1 293 (7.1) 25 (4.3) 10 (2.8) 253 (10.8) 5 (0.6)
2 1090 (26.7) 170 (29.1) 60 (16.6) 764 (32.7) 96 (12.0)
3 864 (21.2) 126 (21.5) 105 (29.1) 258 (11.0) 375 (46.8)
Unknown 1837 (45.0) 264 (45.1) 186 (51.5) 1061 (45.5) 326 (40.6)
Breast surgery (%)
Breast conserving surgery 1835 (44.9) 304 (52.0) 169 (46.8) 967 (41.4) 395 (49.3)
Mastectomy 2249 (55.1) 281 (48.0) 192 (53.2) 1369 (58.6) 407 (50.7)
Axillary surgery (%)
SLNB 1483 (36.3) 257 (43.9) 123 (34.1) 791 (33.9) 312 (38.9)
ALND 2601 (63.7) 328 (56.1) 238 (65.9) 1545 (66.1) 490 (61.1)
Breast pCR (%) 986 (24.1) 236 (40.3) 247 (68.4) 208 (8.9) 295 (36.8)
Includes adenocarcinoma not further defined, mucinous adenocarcinoma, medullary carcinoma, metaplastic carcinoma among other things.
ALND indicates axillary lymph node dissection; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; SLNB, sentinel lymph node biopsy; Triple negative,
negative for ER, PR, and HER2.
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153) without breast pCR (P < 0.001). In the case of cN1 with breast
pCR, 51.8% (58 of 112) of the patients had ypN0 compared to 19.9%
(39 of 196) without breast pCR (P < 0.001) (Table 4).
ER-HER2R subtype
In the ER-HER2þ subtype, trastuzumab in neoadjuvant set-
ting was administered in 336 out of 361 (93.1%) patients. In this
subtype, 247 out of 361 (68.4%) patients achieved breast pCR. In
patients with breast pCR, 67.6% (167 of 247) had ypN0 compared to
46.5% (53 of 114) without breast pCR (P < 0.001). All cN0 patients
with breast pCR (n ¼ 97) had ypN0 compared to 90.3% (28 of 31)
without breast pCR (P¼ 0.013). In the case of cN1 with breast pCR,
46.7% (70 of 150) of the patients had ypN0 compared to 30.1% (25 of
83) without breast pCR (P ¼ 0.014).
ERRHER2S subtype
In the ERþHER2 subtype, 208 out of 2336 (8.9%) patients
achieved breast pCR of whom 58.2% (121 of 208) had ypN0
TABLE 2. Overview of Number of Lymph Node Metastases for Each Breast Cancer Subtype Differentiated Between Breast pCR
and Without Breast pCR After NST
Number of Lymph Node Metastases on Final Pathology (%)
Breast pCR (n ¼ 986) 0 1 2 3 4
ERþHER2þ (n ¼ 236) cT1N0 29 (100) 0 0 0 0
cT2N0 73 (99) 1 (1) 0 0 0
cT3N0 20 (95) 1 (5) 0 0 0
cT1N1 9 (60) 6 (40) 0 0 0
cT2N1 33 (53) 26 (42) 0 2 (3) 1 (2)
cT3N1 16 (46) 17 (48) 0 1 (3) 1 (3)
ER-HER2þ (n ¼ 247) cT1N0 13 (100) 0 0 0 0
cT2N0 72 (100) 0 0 0 0
cT3N0 12 (100) 0 0 0 0
cT1N1 12 (48) 13 (52) 0 0 0
cT2N1 33 (43) 42 (55) 1 (1) 1 (1) 0
cT3N1 25 (52) 23 (48) 0 0 0
ERþHER2 (n ¼ 208) cT1N0 27 (94) 1 (3) 1 (3) 0 0
cT2N0 44 (94) 3 (6) 0 0 0
cT3N0 12 (92) 1 (8) 0 0 0
cT1N1 4 (17) 12 (49) 4 (17) 0 4 (17)
cT2N1 25 (35) 33 (46) 6 (8) 2 (3) 6 (8)
cT3N1 9 (39) 10 (43) 0 2 (9) 2 (9)
Triple negative (n ¼ 295) cT1N0 29 (97) 0 1 (3) 0 0
cT2N0 99 (100) 0 0 0 0
cT3N0 2 (67) 1 (33) 0 0 0
cT1N1 16 (49) 15 (45) 1 (3) 0 1 (3)
cT2N1 47 (47) 45 (44) 6 (6) 1 (1) 2 (2)
cT3N1 16 (55) 10 (35) 2 (7) 0 1 (3)
Number of Lymph Node Metastases on Final Pathology (%)
No Breast pCR (n ¼ 3098) 0 1 2 3 4
ERþHER2þ (n ¼ 349) cT1N0 25 (83) 5 (17) 0 0 0
cT2N0 87 (89) 8 (8) 2 (2) 0 1 (1)
cT3N0 18 (72) 5 (20) 1 (4) 0 1 (4)
cT1N1 9 (33) 10 (37) 2 (7) 1 (4) 5 (19)
cT2N1 15 (13) 63 (53) 10 (8) 7 (6) 24 (20)
cT3N1 15 (30) 13 (26) 4 (8) 3 (6) 15 (30)
ER-HER2þ (n ¼ 114) cT1N0 2 (100) 0 0 0 0
cT2N0 14 (88) 2 (12) 0 0 0
cT3N0 12 (92) 0 1 (8) 0 0
cT1N1 2 (50) 0 0 2 (50) 0
cT2N1 14 (33) 13 (30) 6 (14) 4 (9) 6 (14)
cT3N1 9 (25) 14 (39) 6 (17) 4 (11) 3 (8)
ERþHER2 (n ¼ 2128) cT1N0 97 (75) 24 (18) 5 (4) 0 4 (3)
cT2N0 341 (67) 124 (24) 23 (4) 10 (2) 12 (3)
cT3N0 107 (53) 58 (29) 11 (5) 4 (2) 23 (11)
cT1N1 7 (4) 63 (34) 34 (18) 19 (10) 63 (34)
cT2N1 36 (5) 217 (31) 111 (16) 88 (13) 249 (35)
cT3N1 22 (6) 72 (18) 45 (11) 46 (12) 213 (53)
Triple negative (n ¼ 507) cT1N0 27 (87) 4 (13) 0 0 0
cT2N0 126 (89) 12 (8) 2 (2) 1 (1) 0
cT3N0 26 (79) 4 (12) 2 (6) 0 1 (3)
cT1N1 5 (12) 15 (37) 4 (10) 5 (12) 12 (29)
cT2N1 35 (20) 64 (36) 20 (11) 15 (8) 45 (25)
cT3N1 7 (9) 18 (22) 10 (12) 7 (9) 40 (52)
ER indicates estrogen receptor; HER2, human epidermal growth factor receptor 2; Triple negative, negative for ER, PR and HER2.
Annals of Surgery  Volume 271, Number 3, March 2020 Correlation Between Breast pCR and ypN0
 2018 The Author(s). Published by Wolters Kluwer Health, Inc. www.annalsofsurgery.com | 577
compared to 28.7% (610 of 2128) without breast pCR (P< 0.001). In
cN0 patients with breast pCR, 6 out of 89 patients (6.7%) had 1 or 2
axillary lymph node metastases at final pathology, compared to
35.3% (298 of 843) without breast pCR (P < 0.001). In cN1 patients
with breast pCR, 31.9% (38 of 119) of the patients had ypN0
compared to 5.1% (65 of 1285) without breast pCR (P < 0.001).
Triple negative subtype
In the triple negative subtype, 295 out of 802 (36.8%) patients
achieved breast pCR of whom 70.8% (209 of 295) had ypN0
compared to 44.6% (226 of 507) without breast pCR (P < 0.001).
In the case of cN0 with breast pCR, only 2 out of 132 patients (1.5%)
had 1 or 2 axillary lymph node metastases at final pathology,
compared to 12.7% (26 of 205) without breast pCR (P < 0.001).
In cN1 patients with breast pCR, 48.5% (79 of 163) of the patients
had ypN0 compared to 15.6% (47 of 302) without breast pCR (P <
0.001).
DISCUSSION
In this study, we have reported on a large cohort of cT1-3N0-1
breast cancer patients who were treated with NST and showed an
overall breast pCR rate of 24.1%.We found that breast pCR achieved
after NST is positively correlated with ypN0. Further, the findings
showed that in the case of breast pCR, 97.7% of cN0 patients had
ypN0 and in the case of cN1 45.0% converted to ypN0. Of all breast
cancer subtypes, only the patients with ERþHER2- subtype were
less likely to have ypN0.
TABLE 3. Univariable and Multivariable Analyses for Clinicopathological Variables and the Outcome ypN0 After NST
Univariable Analysis Multivariable Analysis
OR 95% CI P Value OR 95% CI P Value
Age
< 35 yrs 1 [reference] 1 [reference]
35–50 yrs 0.70 0.54–0.90 P < 0.006 0.91 0.55–1.50 P ¼ 0.72
50–75 yrs 0.61 0.47–0.79 P < 0.001 0.90 0.55–1.48 P ¼ 0.68
>75 yrs 0.60 0.21–1.74 P ¼ 0.35 1.55 0.20–12.15 P ¼ 0.68
Clinical tumor stage
T1 1 [reference] 1 [reference]
T2 0.89 0.75–1.06 P ¼ 0.20 0.89 0.64–1.24 P ¼ 0.49
T3 0.51 0.41–0.62 P < 0.001 0.59 0.40–0.87 P ¼ 0.007
Clinical nodal stage
N0 1 [reference] 1 [reference]
N1 0.06 0.05–0.07 P < 0.001 0.03 0.02–0.04 P < 0.001
Tumor histology
Ductal 1 [reference] 1 [reference]
Lobular 0.84 0.68–1.03 P ¼ 0.089 0.93 0.63 –1.37 P ¼ 0.70
Other 0.98 0.79–1.21 P ¼ 0.83 0.89 0.59–1.36 P ¼ 0.60
Tumor grade
1 1 [reference] 1 [reference]
2 1.09 0.84–1.41 P ¼ 0.53 1.01 0.71–1.45 P ¼ 0.95
3 1.67 1.28–2.19 P < 0.001 1.12 0.74–1.69 P ¼ 0.59
Tumor subtype
ERþHER2þ 1 [reference] 1 [reference]
ER-HER2þ 1.06 0.81–1.38 P ¼ 0.70 1.16 0.68–1.98 P ¼ 0.60
ERþHER2 0.31 0.26–0.37 P < 0.001 0.30 0.20–0.44 P < 0.001
Triple negative 0.80 0.65–0.96 P ¼ 0.045 0.95 0.62–1.45 P ¼ 0.81
Breast Pcr
No 1 [reference] 1 [reference]
Yes 4.22 3.62–4.93 P < 0.001 4.53 3.27–6.28 P < 0.001
CI indicates confidence interval; ER, estrogen receptor; OR, odds ratio; Triple negative, negative for ER, PR, and HER2.
TABLE 4. Overview of ypN0 in the Case of Breast pCR and Without Breast pCR After NST for the Different Breast Cancer
Subtypes
Breast pCR and ypN0 No Breast pCR and ypN0 P Value
cT1-3N0 ERþHER2þ (n ¼ 277) 98.4 (122/124) 85.0 (130/153) P < 0.001
cT1-3N1 ERþHER2þ (n ¼ 308) 51.8 (58/112) 19.9 (39/196) P < 0.001
cT1-3N0 ER-HER2þ (n ¼ 128) 100 (97/97) 90.3 (28/31) P ¼ 0.013
cT1-3N1 ER-HER2þ (n ¼ 233) 46.7 (70/150) 30.1 (25/83) P ¼ 0.014
cT1-3N0 ERþHER2 (n ¼ 932) 93.3 (83/89) 64.7 (545/843) P < 0.001
cT1-3N1 ERþHER2 (n ¼ 1404) 31.9 (38/119) 5.1 (65/1285) P < 0.001
cT1-3N0 triple negative (n ¼ 337) 98.5 (130/132) 87.3 (179/205) P < 0.001
cT1-3N1 triple negative (n ¼ 465) 48.5 (79/163) 15.6 (47/302) P < 0.001
Data are presented as percentages with the numbers in parentheses.
x2 test and Fisher exact test between patients with breast pCR and ypN0 versus patients without breast pCR and ypN0.
ER indicates estrogen receptor; Triple negative, negative for ER, PR, and HER2.
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Recently, Tadros et al14 have demonstrated that breast pCR is
strongly correlated with axillary nodal status after NST. They showed
a total breast pCR rate of 36.6% (193 of 527) with a slightly higher
rate of breast pCR in the triple negative group (37.5%) compared to
the HER2þ group (35.7%). In contrast to the Tadros et al study,
patients with clinical T3 stage and ERþHER2 subtype were also
included in the present study which can explain the lower total breast
pCR rate here. We found that in the case of ERþHER2 breast
cancer, pCR rates of the breast and axilla were lower compared to the
other breast cancer subtypes. For this subtype, the most important
systemic therapy (ie, hormonal therapy) generally follows in the
adjuvant setting. Previous studies had reported breast and axillary
pCR rates for the ERþHER2 subtype ranging from 7.5% to
16.5%.4,7,8 We have shown similar breast pCR rates, but higher
ypN0 rates due to the included number of cN0 patients. In the Tadros
et al study, all 527 cT1-2N0 patients with HER2þ and triple negative
breast cancer who achieved breast pCR after NSTwere found to have
ypN0.14 We have confirmed this strong correlation here between
breast pCR and ypN0 in cN0 patients for ERþHER2þ, ER-HER2þ,
and triple negative breast cancer subtypes.
Due to the presence of more effective treatment regimens,
pCR rates in the breast and axilla have improved dramatically over
the past decade.19 Ongoing trials are currently evaluating the accu-
racy of image-guided minimally invasive techniques for predicting
breast pCR in order to potentially omit surgery.20,21 In the MICRA
trial, biopsies of the original tumor bed are obtained after NST
and prior to surgery in all patients with complete or partial radiologic
response evaluated by MRI.20 Preliminary results show that ultra-
sound-guided biopsies identify breast pCR successfully in 91.4%
(43 out of 47) of the patients after NST. In a study by Kuerer et al,22
FNAC and image-guided vacuum-assisted biopsy of the tumor bed
accurately identified breast pCR after chemotherapy in 98.0%
(38 out of 40) of the patients with a false negative rate (FNR) of
5.0%. The Kuerer et al findings have resulted in a prospective clinical
trial evaluating omission of breast surgery after NST in patients with
breast pCR confirmed by image-guided tissue sampling.21
Identifying breast pCR appears important for guiding axillary
treatment given the previously shown correlation between breast and
axillary pCR.13,14 If breast pCR after NST can be identified prior to
surgery, resulting in the complete omission of breast surgery, how should
the axillary lymph nodes be handled in such patients? In recent years the
focus has been on minimizing axillary surgery in an aim to reduce
surgical morbidity. In this study, we observed that 97.7% of cN0 breast
cancer patientswho achievedbreast pCRhadypN0.This implies that the
risk of missing patients with axillary lymph node metastases in these
selected patients is highly unlikely. Therefore, these patients should
proceed to clinical trials to evaluate the safety of omission of axillary
surgery when breast pCR after NST is identified by image-guided tissue
sampling.21 The requirement to proceed in these clinical trials is the
determination of the axillary nodal status before NSTadministration by
axillary ultrasound with or without biopsy.
In our study, only 45.0% of all cN1 patients who achieved
breast pCR also had ypN0. Consequently, these cN1 patients remain
at risk of having axillary lymph node metastases at final pathology,
irrespective of breast pCR, and omission of axillary surgery would
therefore be inappropriate. The performance of imaging techniques
for assessing residual disease in the axillary lymph nodes after NST
remains inaccurate.23,24 As for these cN1 patients, minimally inva-
sive surgical methods for accurately predicting the axillary status are
currently under investigation. These minimally invasive techniques
aim to identify ypN0 after NST resulting in less ALND and thereby
preventing the associated morbidity. Caudle et al showed in a
retrospective study of 85 clinically node positive patients that SLNB
in combination with selective removal of metastatic marked nodes
for predicting ypN0 after NST has a FNR of 2.0%.25 The Dutch
RISAS trial is a currently ongoing prospective multicenter study to
validate this combined procedure of SLNB and MARI (marking the
axillary lymph nodes with radioactive seeds) for identifying ypN0
after NST in clinically node positive patients.26
Limitations
This study included patients from all institutions in the
Netherlands and thereby an advantage is generalizability of the results.
However, our study has certain limitations. Due to the retrospective
nature of the data, there can be no guarantee that all patients completed
NST and, therefore, were treated sufficiently, since this may have
contributed to not obtaining breast and/or axillary pCR. Additionally,
the number of excluded patients as a consequence of missing data
could have affected our results, such as unknown pathological tumor
stage and breast cancer subtype.
CONCLUSIONS
These results indicate that cN0 patients who achieve breast pCR
after NSTare highly likely to achieve ypN0, especially in ERþHER2þ,
ER-HER2þ, and triple negative breast cancer subtypes. Besides guiding
omission of breast surgery, identifying breast pCR may guide de-
escalating axillary treatment with the potential to omit axillary surgery
in selectedpatients.Future clinical trials should investigate if omissionof
axillary surgery in these selected patients is safe when image-guided
tissue sampling identifies breast pCR after NST.
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